Physiology is becoming the next boardroom obsession with employers deploying wearable healthtech to track performance, says Paul Armstrong

There’s a growing gap between how businesses model risk and how performance actually degrades. Corporate performance is still described through revenue growth, operating margin, capital efficiency and market share, yet the real constraint on execution increasingly sits elsewhere. Human physiology now lies directly between strategic intent and operational reality. For finance leaders, physiological and psychological capacity has become a balance-sheet exposure rather than a lifestyle curiosity. Boardrooms debate AI transformation, productivity and resilience while senior executives monitor their sleep apps at 3am, hoping personal optimisation compensates for organisational neglect. But what about the rest of the team?

Strategy looks good on paper, but biology doesn’t cooperate

AI, strategy reviews, digital programmes and cost controls continue to dominate executive attention, but few companies are looking at human decline with such rigour. Traditional P&L isn’t remotely related to chronic sleep debt, metabolic instability, sustained stress and age-related cognitive slowdown, although measurement for each exists and is improving rapidly. Research linking health decline to absenteeism, judgement error and lost productivity continues to harden, yet those costs remain diffuse, poorly owned and rarely modelled. Tech is quietly changing this, largely thanks to the wearable market, which is set to become a $232bn industry by 2030 (GlobalData) in large part through more sophisticated health monitoring.

A small number of organisations have already adjusted behaviour, understandably without much public fanfare. Healthcare vertical integration strategies recognised early that outcomes shape enterprise economics more reliably than........

© City A.M.